Uterine carcinosarcomas: 8-year single center experience of 25 cases

• Published in: Indian journal of medical and paediatric oncology 2011-07, Vol.32 (3), p.149-153
• Main Authors: Dave, Kalpana S, Chauhan, Anjana, Bhansali, Ronak, Arora, Ruchi, Purohit, Sushma
• Format: Article
• Language: English
• Subjects: Analysis; Cancer; Care and treatment; Medical research; Medicine, Experimental; Oncology; Oncology, Experimental; Original; ORIGINAL ARTICLE; Tumors; Uterine cancer
• ISSN: 0971-5851; 0975-2129
• DOI: 10.4103/0971-5851.92814

Abstract Objectives: The aim of this retrospective study was to evaluate the behavior and treatment outcomes of uterine carcinosarcomas in relation to their clinical and pathogenic features and to determine the optimal treatment strategy. Secondary objectives were to identify parameters predictive of survival. Materials and Methods: The hospital records of all 25 patients of uterine carcinosarcoma operated between 2000 and 2008 in Gujarat cancer research institute, Ahmedabad, were reviewed. Patients who presented with clinical evidence of recurrent disease or those who had incomplete medical records were excluded from our analysis. The status of these patients was updated up to November, 2010. Patients were classified according to the new 2009 FIGO staging system for endometrial carcinoma, to see what difference the assigned stage has on survival with the old treatment strategy. Survival was calculated by Kaplan-Meier method and compared by Log-Rank test. Median survival time was derived with the Brookmeyer 95% confidence interval. For comparison of qualitative data, Chi-Square test and Fisher extract c2 were used. Results: Median age of patients was 56 years (range, 36-77 years). Only 36% of patients had stage I at diagnosis and another 36% were stage III. Most of the tumors (56%) were with homologous sarcomatous components and 64% of tumors were high grade (grade 2/3) at diagnosis. Fifty-two percent patients received postoperative adjuvant treatment. Twelve patients had no postoperative treatment: two were lost to follow-up immediately after surgery, four could not receive adjuvant treatment on account of severe medical complications and age factor which could have increased morbidity, and six patients declined treatment. Four of these patients expired within one year of diagnosis, two other within 18 months, and rest were lost to follow-up. The difference in survival of 13 patients who had taken adjuvant treatment was significantly more than the group who had not taken adjuvant therapy ( P =0.025). The overall 3-year disease-free survival of 13 patients who had taken adjuvant therapy was 40%. However, these adjuvant treatment modalities had borderline statistical significance on overall survival of patients ( P =0.075). The only statistically significant predictor of survival in this study was stage of the disease ( P =0.035). Conclusions: This highly aggressive uterine malignancy warrants comprehensive surgical staging to assess tumor dissemination fol